Patent · US Active

Compounds for enzyme inhibition

US8088741B2 · kind B2 · utility

36Cited by
30References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 9, 2005
Grant dateJan 3, 2012
Priority date
Expiry dateAug 29, 2027

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.